Acute hepatotoxicity is a rare adverse effect of intravenous administration of amiodarone, but may be fatal if not recognized early and treated in a timely manner. Herein we report two cases of acute liver failure after intravenous administration of amiodarone. One patient with cerebral infarction was admitted to our emergency department. He received intravenous amiodarone for the acute heart failure with paroxysmal atrial fibrillation (PAF). The patient developed acute liver failure (ALF) and died of multiple organ failure (MOF). The other patient was admitted to our emergency department due to PAF. Intravenous amiodarone was administrated and the PAF was converted to a normal sinus rhythm 6 hours later. The patient developed ALF and acute renal failure (ARF). He was successfully treated with blood purification in combination with other conservative therapy. Neither patient had a history of alcohol abuse or hepatitis virus infection. Furthermore, abdominal ultrasound examinations showed no significant findings in either patient.
Most published reports on acute hepatitis following amiodarone administration show a similar pattern of symptoms and laboratory results, including elevated alanine aminotransferase, aspartate aminotransferase, and total bilirubin, but severe renal impairment is rare. In general, liver injury is rapidly reversible after discontinuation of amiodarone and the fatality rate is low. As shown in Table 1 , we have found five case reports of fatal hepatotoxicity caused by intravenous amiodarone, published between 1984 and 2010. 1e4 Intravenous amiodarone was used in all five cases to treat supraventricular tachyarrhythmia, which is not regarded as the best indication of amiodarone. ARF was the major cause of death in patients with intravenous amiodarone-induced ALF. Although there are no randomized trials to confirm its efficacy, early continuous renal replacement therapy has become a major part of the management of patients with ARF and ALF.
The mechanism for intravenous amiodarone-induced hepatotoxicity is not fully understood. Polysorbate 80, an excipient used to maintain the stability of amiodarone in solution, is believed to be responsible for the hepatotoxicity. However, a recent caseecontrol study argues that hepatotoxicity induced by intravenous amiodarone cannot be clearly differentiated from ischemic hepatitis, claiming that they are in fact the same entity. 5 Future studies should focus on the underlying mechanisms for intravenous amiodarone-induced ALF and ARF.
In summary, hepatotoxicity is a rare, but potentially fatal, adverse effect of intravenous amiodarone. Amiodarone indication should be followed precisely and hepatic and renal parameters should be carefully monitored during and after its administration. Early continuous hemofiltration may improve the prognosis of severe cases of acute renal and liver failures after amiodarone administration. Drug-induced acute liver failure
